ACCEPTANCE OF INDIRECT COMPARISONS IN THE GERMAN EARLY BENEFIT ASSESSMENT

被引：0
|
作者：
Berkemeier, F. [1 ]
Bless, H. [1 ]
Reindl, S. [2 ]
Ballhausen, A. [3 ]
Maltz, A. [2 ]
机构：
[1] IGES Inst GmbH, Berlin, Germany
[2] IGES Inst GmbH, Nurnberg, Germany
[3] IGES Inst GmbH, Hamburg, Germany
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1597
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP64
引用
收藏
页码：A663 / A663
页数：1
相关论文
共 50 条
  • [41] Rank Reversal in Indirect Comparisons
    Norton, Edward C.
    Miller, Morgen M.
    Wang, Jason J.
    Coyne, Kasey
    Kleinman, Lawrence C.
    [J]. VALUE IN HEALTH, 2012, 15 (08) : 1137 - 1140
  • [42] Indirect comparisons of competing interventions
    Glenny, AM
    Altman, DG
    Song, F
    Sakarovitch, C
    Deeks, JJ
    D'Amico, R
    Bradburn, M
    Eastwood, AJ
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2005, 9 (26) : 1 - +
  • [43] Indirect treatment comparisons and biologics
    Mauger, David
    Apter, Andrea J.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (01) : 84 - 86
  • [44] DATA ON PATIENT-REPORTED OUTCOMES IS NOT A PREREQUISITE FOR ACHIEVING AN ADDITIONAL BENEFIT IN GERMAN EARLY BENEFIT ASSESSMENT OF NEW MEDICINAL PRODUCTS APPROVED FOR DERMATOLOGICAL DISEASES
    Gabriel, M. R.
    Specks, J.
    Duetting, S.
    Damen, D.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S338 - S338
  • [45] Research on Assessment Model for The Indirect Economic Benefit of Solid Waste Sanitary Landfill
    Shao, Guoxia
    Wang, Lei
    [J]. MATERIALS, TRANSPORTATION AND ENVIRONMENTAL ENGINEERING, PTS 1 AND 2, 2013, 779-780 : 1272 - 1275
  • [46] BENEFIT RISK COMPARISONS IN THERAPY
    OBEL, AOK
    [J]. EAST AFRICAN MEDICAL JOURNAL, 1983, 60 (04) : 201 - 202
  • [47] IS THE DOOR FOR RWE IN BENEFIT ASSESSMENT IN GERMAN HTA NOW OPEN?
    Emich, H.
    Schmetz, A.
    Prawitz, T.
    Raluy-Callado, M.
    [J]. VALUE IN HEALTH, 2020, 23 : S670 - S670
  • [48] EXTRAPOLATION IN GERMAN BENEFIT ASSESSMENT: THE CHALLENGING REQUIREMENTS FOR PEDIATRIC PHARMACEUTICALS
    Ernst, N.
    Rietzschel, N.
    [J]. VALUE IN HEALTH, 2019, 22 : S636 - S637
  • [49] Fingolimod (Gilenya®) - Pricing Based on the early benefit Assessment
    Fritze, Juergen
    [J]. PSYCHOPHARMAKOTHERAPIE, 2011, 18 (03): : 127 - 130
  • [50] Subgroups in the early benefit assessment of pharmaceuticals: a methodical review
    Rasch, Andrej
    Dintsios, Charalabos-Markos
    [J]. ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2015, 109 (01): : 69 - 78
12345